NATURE NEUROSCIENCE is a premier journal published by NATURE PORTFOLIO, focusing on cutting-edge research in the field of neuroscience. With an esteemed impact factor that reflects its significance in the academic community, this journal occupies an exceptional place in the 2023 Q1 category for neuroscience (miscellaneous) and boasts a leading Scopus rank of #1 out of 113 in general neuroscience, placing it within the top 1st percentile. Since its inception in 1998, NATURE NEUROSCIENCE has consistently delivered high-quality, peer-reviewed articles that contribute to our understanding of the nervous system, driving innovation and scholarship across disciplines. Although it does not offer open access, the journal remains a vital resource for researchers, professionals, and students seeking to stay at the forefront of neuroscientific discovery and discussion. Its editorial commitment to excellence ensures that it continually shapes the trajectory of neuroscience research well into 2024 and beyond, making it an indispensable asset for anyone passionate about the brain and its complexities.

Nature Reviews Neurology, published by NATURE PORTFOLIO, stands as a leading scholarly journal dedicated to the field of neurology and neuroscience. With an impressive impact factor and a prestigious Q1 categorization in both Cellular and Molecular Neuroscience and Clinical Neurology, this journal provides cutting-edge reviews and insights into the latest research developments, trends, and clinical practices. Based in the United Kingdom and accessible to a global audience, Nature Reviews Neurology aims to foster knowledge dissemination and interdisciplinary collaboration among researchers, healthcare professionals, and educators. With an influential Scopus ranking, it remains a pivotal resource for those seeking to deepen their understanding of neurological disorders and therapies while remaining at the forefront of academic discourse and innovation in the field.

Molecular Neurodegeneration is a leading journal published by BMC, dedicated to advancing the field of neurodegeneration through high-quality, open-access research. Since its inception in 2006, this peer-reviewed journal has provided a pivotal platform for the dissemination of innovative findings in the realms of Cellular and Molecular Neuroscience, Molecular Biology, and Clinical Neurology. With a stellar impact factor and listed in the prestigious Q1 category in multiple relevant categories, it ranks among the top publications in the field—specifically, it holds the #3 position in Neuroscience and #6 position in Clinical Neurology based on Scopus metrics. Researchers, professionals, and students alike will find significant value in the open access format, which fosters unrestricted sharing of knowledge, ensuring that emerging ideas in neurodegeneration reach a global audience. Based in London, United Kingdom, the journal promises a comprehensive scope that addresses critical questions in neurobiology, making it an essential resource for anyone interested in the molecular mechanisms underlying neurodegenerative diseases.

Welcome to Molecular Neurobiology, the premier journal dedicated to the exploration of the molecular mechanisms underlying nervous system function and pathophysiology. Published by Springer, this journal provides an essential platform for disseminating high-quality research in the rapidly evolving fields of Cellular and Molecular Neuroscience and Neurology, boasting an impressive impact factor that reflects its esteemed position within the academic community. With its ranking in the Q1 and Q2 quartiles for various neuroscience categories, Molecular Neurobiology stands at the forefront of groundbreaking discoveries, showcasing innovative studies that bridge basic science and clinical application. Researchers and professionals are invited to contribute to its rich portfolio, which spans from fundamental insights into cellular processes to advanced therapeutic strategies. Although Molecular Neurobiology does not operate as an Open Access journal, its influential body of work remains accessible through institutional and personal subscriptions. As we converge from 1987 to 2024, we continue to aim for excellence, seeking to catalyze progress in understanding neurological diseases and enhance the scientific dialogue within the neuroscience community.

CELLULAR AND MOLECULAR NEUROBIOLOGY, published by SPRINGER/PLENUM PUBLISHERS, stands as a significant contributor to the fields of cell biology and neuroscience, holding a distinguished position in the academic community with an impact factor that places it in the Q2 category for both Cell Biology and Cellular and Molecular Neuroscience, along with Q1 in Medicine (miscellaneous). Since its inception in 1981, this journal has provided a critical platform for innovative research and thought-provoking reviews, fostering a deeper understanding of complex neurobiological mechanisms. The journal’s rigorous peer-review process ensures the publication of high-quality manuscripts that offer valuable insights into cellular processes and neural functions. With a commitment to advancing knowledge and promoting collaboration among researchers, CELLULAR AND MOLECULAR NEUROBIOLOGY remains an essential resource for professionals and students alike, looking to stay updated on the latest developments in neurobiology.

Neurochemical Journal, published by MAIK NAUKA/INTERPERIODICA/SPRINGER, focuses on the dynamic and rapidly evolving field of neurochemistry, providing insights into cellular and molecular neuroscience. Despite the discontinuation of its coverage in Scopus, the journal remains a valuable resource for researchers and professionals seeking to explore the biochemical underpinnings of neural function and pathophysiology. With an ISSN of 1819-7124 and an E-ISSN of 1819-7132, the journal aims to publish rigorous research articles, reviews, and notes that push the boundaries of our understanding of neurochemical processes. With a ranking that places its subjects in the lower quartile of their respective fields, Neurochemical Journal offers a platform for innovative studies and discussions among up-and-coming scientists, making it a crucial outlet for advancing the discourse in this critical area of biomedical research.

FOLIA NEUROPATHOLOGICA is a distinguished Open Access journal specializing in the fields of Neurology and Pathology, published by the reputable TERMEDIA PUBLISHING HOUSE LTD. With an ISSN of 1641-4640 and E-ISSN 1509-572X, this journal has been a vital resource for the dissemination of high-quality research since its inception in 1994. Covering a broad spectrum of topics within neuropathology, the journal emphasizes clinical findings and forensic implications, making it an essential platform for healthcare professionals, researchers, and students alike. With impressive impact factors positioning it in the Q3 category for both Neurology (clinical) and Pathology and Forensic Medicine, FOLIA NEUROPATHOLOGICA occupies a significant place among its peers, ranked within the 36th to 46th percentiles on Scopus. Scholars can benefit from the Open Access model implemented since 2005, ensuring wide accessibility and distribution of critical research outputs aimed at advancing both clinical practices and academic knowledge. Based in Poland, at KLEEBERGA 2, POZNAN 61-615, this journal continues to shape the discourse in neuropathology and related fields.

Current Molecular Pharmacology, published by Bentham Science Publishers, is a prominent journal focused on the dynamic fields of pharmacology, drug discovery, and molecular medicine. With an ISSN of 1874-4672 and an E-ISSN of 1874-4702, this journal aims to disseminate cutting-edge research and review articles that showcase innovative methodologies and groundbreaking findings from 2008 through 2024. Holding a respectable Q3 category ranking in Drug Discovery, Molecular Medicine, and Pharmacology for 2023, Current Molecular Pharmacology serves as an essential platform for both established researchers and emerging scholars to share their insights. The journal is indexed in Scopus with its relevant ranks catering to pharmacology and molecular biology, ensuring it reaches a wide array of professionals, researchers, and students in the field. As a contributor to advancing pharmacological sciences, this journal provides invaluable access to the latest advancements and fosters ongoing dialogue in molecular pharmacology, positioning itself as a key resource in the exploration of therapeutic agents and their interactions.

Translational Neuroscience, published by DE GRUYTER POLAND SP Z O O, is a leading open-access journal since its inception in 2015, dedicated to the multidisciplinary exploration of neurological research and its clinical applications. With an ISSN of 2081-3856 and an E-ISSN of 2081-6936, the journal serves as a crucial platform for scholars and practitioners to disseminate innovative findings and theoretical advancements in the field of neuroscience. Covering various aspects of general neuroscience, it is ranked in the Q3 quartile for 2023 and positioned at Rank #75 out of 113 in its category, reflecting its growing impact within the scientific community. The journal strives to bridge the gap between laboratory research and clinical practice, fostering collaboration among researchers, clinicians, and educators. The editorial team is committed to maintaining high publication standards that engage the audience with rigorous research while promoting a culture of open science. For those interested in the forefront of neuroscience research, Translational Neuroscience offers an invaluable resource for knowledge and innovation.

EXPERIMENTAL NEUROLOGY is a premier academic journal published by Academic Press Inc, Elsevier Science, focusing on advancements in the fields of Developmental Neuroscience and Neurology. With an impressive Impact Factor and ranked in the Q1 quartile of both categories—positioning it among the top-tier journals—this publication has established itself as a vital resource for researchers, clinicians, and students alike. Since its inception in 1959, it has fostered the dissemination of cutting-edge research and innovative approaches to understanding neurological function and related disorders. While EXPERIMENTAL NEUROLOGY currently operates under a subscription access model, its rich archives and ongoing contributions to the field continue to inspire and inform the next generation of neurobiologists. The journal also boasts a high ranking in Scopus, placing fourth in Developmental Neuroscience and twentieth in Neurology, indicating its robust influence and scholarly significance. For those committed to advancing knowledge in these critical areas, EXPERIMENTAL NEUROLOGY is an indispensable platform for inquiry and discovery.